Journal of Psychopharmacology
November 1, 2007
Ben Sessa, David Nutt
39 citations
3,4-Methylenedioxymethlyamphetamine (MDMA) has penetrated extensively into our culture in the last thirty years. It started life in medicine when adopted as a clinical tool by psychotherapists on the West Coast of America who used it as an alternative to the then banned LSD for facilitating interactions in couples’ therapy. From the therapist’s couch the drug leaked into public use, with a...
Synapse
October 25, 2007
Noelia Granado, Isabel Escobedo, Esther O’shea et al.
59 citations
Abstract The amphetamine analogue 3,4‐methylenedioxymethamphetamine (MDMA or “Ecstasy”) is a popular drug of abuse which causes different neurotoxic effects in the mouse compared with the rat. In mice, MDMA produces damage to striatal dopamine terminals, having little long‐term effects on serotonin (5‐HT) containing neurons. A relevant feature of the striatum is its striosome/matrix...
Journal of Forensic Sciences
October 18, 2007
Ruth Smith
38 citations
Abstract: Profiling illicit ecstasy tablets has the potential to become an invaluable tool in the crackdown on drug trafficking, but that potential has yet to be fully realized. The impurity profile of an ecstasy tablet can be used to determine the method employed to synthesize the actual controlled substance, which in most cases, is 3,4‐methylenedioxymethamphetamine (MDMA). Tablets can then be...
Addiction Biology
October 2, 2007
Firas H Kobeissy, Jennifer A. Jeung, Matthew W Warren et al.
47 citations
ABSTRACT Club drug abuse is a growing problem in the United States. Beyond addiction and toxicity are endocrine effects which are not well characterized. Specifically, the changes in appetite following exposure to drugs of abuse are an interesting but poorly understood phenomenon. Serum hormones such as leptin, ghrelin, growth hormone (GH), and neuropeptide‐Y (NP‐Y) are known to affect...
Pharmacology, Biochemistry, and Behavior
October 2007
Kevin T. Ball, Kelly M Walsh, George V. Rebec
The widely used recreational drug MDMA (ecstasy) supports self-administration in animals, but it is not known whether MDMA-associated cues are able to reinstate drug seeking in a relapse model of drug addiction. To assess this possibility, drug-naïve rats were trained to press a lever for MDMA infusions (0.30 mg/kg/infusion, i.v.) paired with a compound cue (light and tone) in daily 2 h...
Drug Metabolism and Disposition
October 2007
Matthew L Banks, Jon E. Sprague, David F Kisor et al.
Changes in ambient temperature are known to alter both the hyperthermic and the serotonergic consequences of 3,4-methylenedioxymethamphetamine (MDMA). Metabolism of MDMA has been suggested to be a requisite for these neurotoxic effects, whereas the hyperthermic response is an important contributing variable. The aim of the present study was to investigate the interaction between ambient...
Psychopharmacology
October 2007
Rosa Hoshi, Kate Mullins, Catherine Boundy et al.
Despite years of research and much controversy surrounding the effects of ecstasy use, findings are equivocal. Attempting to reduce methodological problems, such as concurrent use of other recreational drugs, could lead to a clearer picture of the effects of ecstasy use on cognitive function. The aim of this study is to investigate the effects of both prolonged abstention from ecstasy use and...
Human Psychopharmacology: Clinical and Experimental
September 25, 2007
Konstantine K. Zakzanis, Zachariah Campbell, Diana Jovanovski
87 citations
Abstract A growing number of empirical studies have found varying neuropsychological impairments associated with use of 3,4‐methylenedioxymethamphetamine (MDMA) use. We set out to determine to what extent neuropsychological abilities are impaired in MDMA users. To do so, meta‐analytical methods were used to determine the magnitude of neuropsychological impairment in MDMA users across...
British Journal of Pharmacology
September 24, 2007
Therese Montgomery, Christophe Buon, S Eibauer et al.
33 citations
Background and purpose: Illegal ‘ecstasy’ tablets frequently contain 3,4‐methylenedioxymethamphetamine (MDMA)‐like compounds of unknown pharmacological activity. Since monoamine transporters are one of the primary targets of MDMA action in the brain, a number of MDMA analogues have been tested for their ability to inhibit [ 3 H]noradrenaline uptake into rat PC12 cells expressing the...
Toxicology and Applied Pharmacology
September 15, 2007
Sara Garcia-Ratés, Jordi Camarasa, Elena Escubedo et al.
Previous work from our group indicated that alpha7 nicotinic acetylcholine receptors (alpha7 nAChR) potentially play a role in methamphetamine (METH) and 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity. The aims of the present study were two-fold: (1) to demonstrate the interaction of METH and MDMA with homomeric alpha7 nAChR ([(3)H]methyllycaconitine binding) and other heteromeric...